Physicians must remember that all drugs have safety risks
Drug Safety
What can the ACR do?
FDA Enforcement Against Injectable Colchicine
The U.S. Food and Drug Administration (FDA) has ordered companies to stop marketing unapproved drug products that contain colchicines in an injectable dosage form.
The Line Between Boost and Ban
What makes a performance-enhancing drug taboo?
Build Up Bone
Current management of osteoporosis
Prior Authorization Struggle Continues
Many Medicare Part D plans continue to request prior authorizations for several drugs commonly prescribed by rheumatologists. The ACR has been working diligently with Robert Bennett of the Physician Regulatory Issues Team (PRIT) to avoid the same problems many physicians had last year. PRIT advises all physicians to write “for Part D” along with the diagnosis on the prescription, to verify that the drugs are for Part D diagnoses and should not be paid under Part B. This way the administrators of the prescription drug plans (PDPs) can waive the need for a new prior authorization—saving time and money for physicians, pharmacists, and the PDPs.
Combine With Medicare Part D to Help Patients Afford Prescriptions
According to the 2003 U.S. Census, 29 million people in the United States make less than 200% of the federal poverty level and have no health insurance. Many persons have difficulty affording prescribed medications. In addition to Medicare Part D, there are more than 350 public and private patient assistance programs, including programs by pharmaceutical companies, that help patients pay for prescriptions.
- « Previous Page
- 1
- …
- 8
- 9
- 10